MedTrace Logo

A Dose-ranging, Study of the Safety and Efficacy of Subcutaneous Injections of LIPO-102 Compared With Placebo for the Reduction of Abdominal Subcutaneous Adiposity

NCT01180465 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2015-03-26

No results posted yet for this study

Summary

LIPO-102 is under evaluation for treatment of abdominal adiposity

Conditions

  • Weight

Interventions

DRUG

LIPO-102

LIPO-102 High dose

DRUG

LIPO-102 Low

LIPO-102 Low dose

DRUG

LIPO-102, Placebo

Placebo

Sponsors & Collaborators

  • Neothetics, Inc

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01180465 on ClinicalTrials.gov